Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Farmakeio Outsourcing LLC is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, indicating a very focused prosecution footprint. For a practitioner, this means that the company's immediate patent goals are tied to the resolution of this single matter and the specific requirements of the assigned examiner.
The company's active prosecution is confined to 1 distinct art unit. This focus on the Biotechnology & Pharmaceuticals sector allows for a more streamlined legal strategy, as there is no need to navigate the different procedural or technical expectations of multiple administrative divisions. Practitioners can dedicate their efforts to understanding the specific nuances of this 1 unit to improve the chances of a successful outcome for the pending application.
CHANG, KYUNG SOOK is the busiest examiner for Farmakeio Outsourcing LLC, currently handling 1 pending office action. As the only examiner with an active case for the company, CHANG, KYUNG SOOK's individual approach to the Biotechnology & Pharmaceuticals field will be the primary factor in the case's progress. Practitioners should analyze this examiner's previous decisions and preferences to effectively address the 1 pending office action and move the application toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANG, KYUNG SOOK | 1 | 60.5% | +40.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18973457 | Steroidal Compositions and Method of Making and Use | CHANG, KYUNG SOOK | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18973457 | Steroidal Compositions and Method of Making and Use | CHANG, KYUNG SOOK | 1613 | §102§103DP | Non-Final OA | — | Pending | Dec 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFarmakeio Outsourcing LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyung Sook Chang has the most, with 1 of Farmakeio Outsourcing LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
